Clinicopathologic implications of the epidermal growth factor receptor, cyclooxygenase 2 expression, and human papillomavirus status in squamous cell carcinoma of the uterine cervix in the elderly

International Journal of Gynecological Cancer

Volumn 21, Issue 2, 2011, Pages 337-348

  Giordano, Giovanna ^a   D'Adda, Tiziana ^a   Dal Bello, Barbara ^b   Brigati, Francesca ^a   Bersiga, Alessandra ^c   Campanini, Nicoletta ^a   Berretta, Roberto ^a   Rocco, Alba ^d   Merisio, Carla ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c CREMONA HOSPITAL   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cyclooxygenase 2 (Cox 2); Epidermal growth factor receptor (EGFR) immunoreactivity; Human papillomavirus (HPV); Invasive squamous cervical carcinoma

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; VIRUS DNA;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; FISHER EXACT TEST; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHUMAN; NONPARAMETRIC TEST; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEXUAL BEHAVIOR; SURVIVAL RATE; UNIVARIATE ANALYSIS; UTERINE CERVIX CARCINOMA; VERRUCA VULGARIS; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; PAPILLOMAVIRUS INFECTIONS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 79956065261     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31820864b7     Document Type: Article

References (52)

1. Rodeck U, Jost M, Kari C, et al. EGF-R dependent regulation of keratinocyte survival. J Cell Sci. 1997;110:113-121. (Pubitemid 27075856)
2. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21:2787-2799. (Pubitemid 46606324)
3. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183-232.
4. Williams CS, DuBois RN. Prostaglandins endoperoxide synthase: why two isoforms? Am J Physiol. 1996;270: G393-G400.
5. Ali-Fehmi R, Morris RT, Bandyopadhyay S, et al. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. Am J Obstet Gynecol. 2005;192:819-825. (Pubitemid 40311275)
6. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell. 1995;83:493-550.
7. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 1997;94:3336-3340. (Pubitemid 27157312)
8. Syrjanen SM, Syrjanen KJ. New concepts on the role of human papillomavirus in cell cycle regulation. Ann Med. 1999;31:175-187. (Pubitemid 29304455)
9. Allen DC. Cervical carcinoma. In: Histopathology Reporting. Guidelines for Surgical Cancer. London: Springer-Verlag; 2006:266-278.
10. Giordano G, D'Adda T, Merisio C, et al. Vulvar acantholytic squamous carcinoma: a case report with immunohistochemical, and molecular study. Int J Gynecol Pathol. 2005;24:303-306. (Pubitemid 40885087)
11. Giordano G, D'Adda T, Gnetti L, et al. Endometrial mucinous microglandular adenocarcinoma: morphologic, immunohistochemical features and emphasis in the HPV status. Int J Gynecol Pathol. 2006;25:77-82. (Pubitemid 44638340)
12. Giordano G, D'Adda T, Gnetti L, et al. Detection of human papillomavirus in organs of upper genital tract in women with cervical cancer. Int J Gynecol Cancer. 2006;16: 1601-1607. (Pubitemid 44060387)
13. Giordano G, D'Adda T, Gnetti L, et al. Role of human papillomavirus in the development of epithelial ovarian neoplasms in Italian women. J Obstet Gynaecol Res. 2008;34:210-217. (Pubitemid 351537736)
14. Lee TS, Jeon YT, Kim JW, et al. Increased cyclooxygenase-2 expression associated with inflammatory cellular infiltration in elderly patients with vulvar cancer. Ann N Y Acad Sci. 2007;1095:143-153.
15. Langner C, Ratschek M, Rehak P, et al. Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation? J Clin Pathol. 2004;57:773-775. (Pubitemid 38901498)
16. Sablinska B. Carcinoma of the uterine cervix in women over 70 years of age. Gynecol Oncol. 1979;7:128-135. (Pubitemid 9155788)
17. Prempree T, Patanaphan V, Sewchand W, et al. The influence of patients' age and tumor grade on the prognosis of carcinoma of the cervix. Cancer. 1983;51:1764-1771. (Pubitemid 13129050)
18. Hale RJ, Buckley CH, Gullick WJ, et al. Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol. 1993;46:149-153. (Pubitemid 23076346)
19. Kersemaekers AMF, Fleuren GJ, Kenter GG, et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res. 1999;5:577-586. (Pubitemid 29131967)
20. Kim YT, Park SW, Kim JW. Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. Gynecol Oncol. 2002;87:84-89. (Pubitemid 36027106)
21. Scambia G, Ferrandina G, Distefano M, et al. Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer. Cancer Lett. 1998;123:135-139. (Pubitemid 28064090)
22. Ferrandina G, Lauriola L, Distefano MG, et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol. 2002;20:973-981. (Pubitemid 34141840)
23. Ryu HS, Chang KH, Yang HW, et al. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol. 2000;76:320-325.
24. Kim GE, Kim YB, Cho NH, et al. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin Cancer Res. 2004;10:1366-1374. (Pubitemid 38365230)
25. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19. (Pubitemid 29406813)
26. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87:796-802.
27. Castellsague X, Diaz M, de Sanjose S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006;98:303-315. (Pubitemid 43338210)
28. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621-632. (Pubitemid 46986496)
29. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88:63-73.
30. Takubo K, Shimomura-Izumiyama N, et al. Detection of human papillomavirus infection of the cervix in very elderly women using PCR. Clin Cancer Res. 2005;11:2919-2923. (Pubitemid 40525193)
31. Baay MF, Tjalma WA, Weyler J, et al. Prevalence of human papillomavirus in elderly women with cervical cancer. Gynecol Obstet Invest. 2001;52:248-251. (Pubitemid 33135378)
32. Nakagawa S, Yoshikawa H, Jimbo H, et al. Elderly Japanese women with cervical carcinoma show higher proportions of both intermediate-risk human papillomavirus types and p53 mutations. Br J Cancer. 1999;79:1139-1144. (Pubitemid 29087887)
33. García-Piñeres AJ, Hildesheim A, Herrero R, et al. Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. Cancer Res. 2006;66:11070-11076. (Pubitemid 44877008)
34. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange. Cancer Res. 2007;67:3976-3985. (Pubitemid 46762188)
35. Grimble RF. Inflammatory response in the elderly. Curr Opin Clin Nutr Metab Care. 2003;6:21-29. (Pubitemid 40684615)
36. Pfeilschifter J, Köditz R, Pfohl M, et al. Changes in proinflammatory cytokine activity after menopause. Endocr Rev. 2002;23:90-119. (Pubitemid 34185307)
37. Zijlmans HJ, Fleuren GJ, Baelde HJ, et al. Role of tumor-derived the migration and differentiation of antigen-presenting cells in cervical carcinoma. Cancer. 2007;109:556-565.
38. Nair A, Venkatraman M, Maliekal TT, et al. NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene. 2003;22:50-58. (Pubitemid 36152883)
39. Pandey M, Bajaj GD, Rath PC. Induction of the interferon-inducible RNA-degrading enzyme, RNase by stress-inducing agents in the human cervical carcinoma cells. RNA Biol. 2004;1:21-27.
40. Branca M, Giorgi C, Ciotti M, et al. Upregulation of nuclear factor-kappaB (NF-kappaB) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus or disease outcome in cervical cancer. Diagn Cytopathol. 2006;34: 555-563. (Pubitemid 44157177)
41. Weinberg R. The Biology of Cancer. New York, NY: Garland Science, Taylor Francis Group, LLC; 2007.
42. Gøtzsche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Control Clin Trials. 1989;10: 31-56. (Pubitemid 19099522)
43. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation. 2005;112: 759-770. (Pubitemid 41099056)
44. Khunamornpong S, Settakorn J, Sukpan K, et al. Cyclooxygenase-2 expression in squamous cell carcinoma of the uterine cervix is associated with lymph node metastasis. Gynecol Oncol. 2009;112:241-247.
45. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493-501.
46. Elder DJ, Halton DE, Hague A, et al. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin. Cancer Res. 1997;3:1679-1683. (Pubitemid 27444704)
47. Kang HJ, Gong G, Jang SJ, et al. Expression of cyclooxygenase-2 in human breast carcinoma: relevance to tumor angiogenesis and expression of estrogen receptor. Cancer Res Treat. 2001;33:286-295.
48. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60:1306-1311. (Pubitemid 30151999)
49. Harari PM, Huang SM. Modulation of molecular targets to enhance radiation. Clin. Cancer Res. 2000;6:323-325. (Pubitemid 30111446)
50. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000;69:145-182.
51. Matsuura H, Sakaue M, Subbaramaiah K, et al. Regulation of cyclooxygenase-2 by interferon γ and transforming growth factor α in normal human epidermal keratinocytes and squamous carcinoma cells. Role of mitogen-activated protein kinases. J. Biol. Chem. 1999;274:29138-29148.
52. Lee JS, Choi YD, Lee JH, et al. Expression of cyclooxygenase-2 in adenocarcinomas of the uterine cervix and its relation to angiogenesis and tumor growth. Gynecol Oncol. 2004;95:523-529.